Last reviewed · How we verify
SHR-1826
At a glance
| Generic name | SHR-1826 |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer (PHASE2)
- A Phase Ib Study of HS-10504 Combined Therapy in NSCLC (PHASE1)
- A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour (PHASE2)
- A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors (PHASE1, PHASE2)
- A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer (PHASE2)
- A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC (PHASE1, PHASE2)
- An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors (PHASE1)
- A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-1826 CI brief — competitive landscape report
- SHR-1826 updates RSS · CI watch RSS
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. portfolio CI